Auto-Tandem Catalysis with Ruthenium: From <i>o</i>
-Aminobenzamides and Allylic Alcohols to Quinazolinones <i>via</i>
Redox Isomerization/Acceptorless Dehydrogenation
作者:Weikang Zhang、Chong Meng、Yan Liu、Yawen Tang、Feng Li
DOI:10.1002/adsc.201800660
日期:2018.10.4
A strategy for the synthesis of quinazolinonesvia Ru‐catalyzed redoxisomerization/acceptorlessdehydrogenation was proposed and accomplished. In the presence of a commercially available [(p‐cymene)Cl2]2, a range of desirable products were obtained with o‐aminobenzamides and allylicalcohols as starting materials in moderate to high yields. This strategy is attractive due to high atom efficiency,
AGONISTS OF THE APELIN RECEPTOR AND METHODS OF USE THEREOF
申请人:Sanford-Burnham Medical Research Institute
公开号:US20170197958A1
公开(公告)日:2017-07-13
Provided herein are small molecule agonists of the apelin receptor for the treatment of disease. The compounds disclosed herein are useful for the treatment of a range of cardiovascular, renal and metabolic conditions. The present invention is based on the seminal discovery of a series of potent small molecule agonists of the apelin receptor, which are useful for the treatment of diseases including heart failure, chronic kidney disease, hypertension, and metabolic disorders such as insulin resistance/diabetes and obesity. The compounds disclosed herein are highly specific for the apelin receptor versus the angiotensin II receptor (ATI).
[EN] AGONISTS OF THE APELIN RECEPTOR AND METHODS OF USE THEREOF<br/>[FR] AGONISTES DU RÉCEPTEUR DE L'APÉLINE ET LEURS PROCÉDÉS D'UTILISATION
申请人:SANFORD BURNHAM MED RES INST
公开号:WO2015184011A2
公开(公告)日:2015-12-03
Provided herein are small molecule agonists of the apelin receptor for the treatment of disease. The compounds disclosed herein are useful for the treatment of a range of cardiovascular, renal and metabolic conditions.